Top 9 Biggest Vaccine Companies In The World
![]() |
The global vaccines industry is forecast to experience a rapid growth spearheaded by the leading vaccine manufacturers in the world who make different types of vaccines. The recent global pandemic of Covid-19 has also had a huge positive impact on this market as many world’s top vaccine companies are now focused on developing the most effective vaccination to combat this highly infectious and life-threatening virus, known as Coronavirus. The global vaccine market is expected to register a strong growth over the next five years as there is intense competition among the list of vaccine manufacturers that are placing greater emphasis on the research and development of live vaccines. The list of vaccines that are commonly administered include diseases like chickenpox, diphtheria, influenza, meningococcal, and Hepatitis A. Several leading vaccine manufacturers are spending heavily to develop vaccination for babies and vaccination schedule for adults in the wake of rising number of diseases that can be prevent with vaccines.
List of 9 Biggest Vaccine Companies In The World
9. Curevac - $19.153 billion
8. Biontech - $29.26 billion
7. Chongqing Zhifei Biological Products - $37.52 billion
6. Moderna - $44.616 billion
5. Glaxo Smith Kline - $96.115 billion
4. Sanofi - $121.45
3. AstraZeneca - $133.055 billion
2. Merck - $210.068 billion
1. Pfizer - $206.383 billion
Detailed information of top 9 biggest vaccine companies in the world
9. Curevac
![]() |
Photo: Getty Images |
CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.
The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations, the International AIDS Vaccine Initiative, and the government of Germany.
Total market cap: $19.153 billion
Total revenue: $19.49 million
8. Biontech
![]() |
Photo: Reuters |
BioNTech SE (short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.
In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which offers a 95% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the UK. It was the first mRNA vaccine ever authorized. Some days later the vaccine also got an emergency approval in the United States, Canada, and Switzerland. On 21 December 2020, the European Commission approved BioNTech/Pfizer's coronavirus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA).
Total market cap: $29.26 billion
Total revenue: $131.43 million
7. Chongqing Zhifei Biological Products
![]() |
Photo: Getty Images |
Chongqing Zhifei Biological Products Co., Ltd. (“Zhifei” or “the Company” for short) has its presence in biological product industry in 2002. The Company achieved an operating income of RMB15.19 billion in 2020 with the support of its nearly 3,300 employees based on its registered capital of RMB1.6 billion and total assets of RMB15.2 billion.In September 2010, Zhifei was listed on the Shenzhen Stock Exchange (stock code: 300122), becoming the first privately-run vaccine enterprise listed on ChiNext. Zhifei has five wholly-owned subsidiaries and a joint-stock subsidiary, of which Beijing ZhifeiLvzhu Biopharmaceutical Co., Ltd. and Anhui ZhifeiLongcom Biopharmaceutical Co., Ltd. are new high-tech enterprises.
As a high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use, which is one of seven strategic emerging industries of China and has a broad development prospect. The commercially available products of the Company include Recombinant Novel Coronavirus Vaccine (CHO Cell),Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) (Ekear®), Haemophilus Influenzae Type b Vaccine (XiFeiBei®), Group ACYW135 Meningococcal Polysaccharide Vaccine (Menwayc®), Mycobacterium Vaccae for Injection (Vaccae®), Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine (Mening A Con®), and other independently developed products. Meantime, Zhifei is the sole distributor of the vaccines of Merck Sharp &Dohme(MSD) such as HPV4(Gradasil),HPV9(Gradasil 9),5-valent rotavirus vaccine(Rotateq),23-valent Pneumonia vaccine(Pneumovax 23),Hepatitis A vaccine(Vaqta).
Total market cap: $37.52 billion
Total revenue of the company: $1.657 billion
6. Moderna
![]() |
Photo: BBC |
The Moderna COVID‑19 vaccine, codenamed mRNA-1273, is a COVID-19 vaccine developed by Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA). It is used in people aged 18 years and older to provide protection against infection by the SARS-CoV-2 virus, which causes COVID-19. It is designed to be administered as two 0.5 mL doses given by intramuscular injection at an interval of four weeks apart.
It is an RNA vaccine composed of nucleoside-modified mRNA (modRNA) encoding a spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles.
The Moderna COVID‑19 vaccine is authorized for use at some level in 45 countries including the United States, Canada, the European Union, the United Kingdom, Israel, and Singapore.
On 15 March 2021, Moderna's second COVID‑19 vaccine (mRNA-1283) started phase I clinical trials.
Total market cap: $44.616 billion
Total revenue: $94.47 million
5. Glaxo Smith Kline
![]() |
Photo: Getty Images |
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co. In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi. It uses a recombinant protein-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021. The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.
Total market cap: $96.115 billion
Total revenue of the company: $40.832 billion
4. Sanofi
![]() |
Photo: Getty Images |
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. Originally, the company was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.
Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur). In 2017, Sanofi's dengue vaccine Dengvaxia garnered controversy because it caused some vaccinated young children to have more cases of severe dengue. The New York Times cited criticism for Sanofi's aggressive ad campaign despite the fact that this new vaccine was not completely safe.
![]() |
3. AstraZeneca
![]() |
Photo: Getty Images |
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company. Cambridge Biomedical Campus in Cambridge, England.It has a portfolio of products for major diseases in areas including oncology , cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It is perhaps best known for its involvement in developing the Oxford-Astrazeneca COVID-19 vaccine.
Total market cap:$133.055 billion
Total revenue of the company: $23.565 billion
2. Merck
![]() |
Photo: Investo |
Merck & Co is considered as among the top vaccine companies in the world and also one of the largest pharmaceutical companies in the world. Merck & Co was founded in 1891 by George Merck in the US. The headquarters of this leading vaccine manufacturer is at New Jersey, US and almost 70,000 individuals work for Merck & Co. The annual sales revenue of Merck & Co is estimated to be around USD 40 billion and some of the top-selling vaccines made by this top vaccine company are GARDASIL, RECOMBIVAX HB, RotaTeq, VARIVAX, and ZOSTAVAX.
Total market cap: $210.068 billion
Total revenue of the company: $46.840 billion
1. Pfizer
![]() |
Photo: Reuters |
On the leading list of vaccine manufacturers, Pfizer consistently ranks among the top 10 vaccine manufacturers in the world. Pfizer was founded in 1849 by Charles Pfizer and Charles F. Erhart with its head office located at New York, US. Pfizer is regarded as one of the top vaccine companies with a global presence and almost 98,000 professionals are employed with the company. The yearly revenue of Pfizer is around USD 50 billion, and the vaccine brands owned by the company include Prevnar 13, NeisVac-C, Mencevax, Nimenrix, and Trumenba.
Total market cap: $206.383 billion
Total revenue of the company: $51.750 billion
![]() China Covid-19 Vaccine Latest News: Check Out the names of vaccines that made in China, How much do they cost? Efficacy, Which Countries Received ... |
![]() If you’ve been administered two doses of COVID-19 vaccine, you can get a certificate and download it online for multiple purposes. Check out We guide ... |
![]() A complete guide on how you can book COVID-19 vaccination. |
![]() Covid-19 in China - Latest News: The Chinese mainland reported seven new COVID-19 cases, all of which were imported, the National Health Commission said in ... |